Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma.

Fradley MG, Groarke JD, Laubach J, Alsina M, Lenihan DJ, Cornell RF, Maglio M, Shain KH, Richardson PG, Moslehi J
Br J Haematol. 2018 180 (2): 271-275

PMID: 29048105 · DOI:10.1111/bjh.14970

MeSH Terms (11)

Adult Antineoplastic Agents, Immunological Antineoplastic Combined Chemotherapy Protocols Cardiotoxicity Electrocardiography Female Heart Diseases Humans Magnetic Resonance Imaging Multiple Myeloma Proteasome Inhibitors

Connections (1)

This publication is referenced by other Labnodes entities: